{"id":"NCT00532935","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","officialTitle":"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of the MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01-26","primaryCompletion":"2009-10-23","completion":"2009-10-23","firstPosted":"2007-09-21","resultsPosted":"2010-10-18","lastUpdate":"2017-06-09"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"sitagliptin phosphate (+) metformin hydrochloride","otherNames":["Janumet"]},{"type":"DRUG","name":"Comparator: pioglitazone","otherNames":["pioglitazone"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 32","timeFrame":"Baseline and Week 32","effectByArm":[{"arm":"Sitagliptin/Metformin Fixed-Dose Combination","deltaMin":-1.86,"sd":null},{"arm":"Pioglitazone","deltaMin":-1.39,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22059736"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":261},"commonTop":["Diarrhoea","Hypoglycaemia","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}